{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T06:01:00Z","timestamp":1774159260381,"version":"3.50.1"},"reference-count":97,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100022344","name":"InflaRx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022344","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.det.2024.12.008","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T12:51:28Z","timestamp":1737463888000},"page":"231-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Managing Hidradenitis Suppurativa with Biologics and Small Molecule Inhibitors"],"prefix":"10.1016","volume":"43","author":[{"given":"Victoria","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhika","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G.","family":"Micheletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.det.2024.12.008_bib1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1159\/000453355","article-title":"Quality of life and psychosocial implications in patients with hidradenitis suppurativa","volume":"232","author":"Kouris","year":"2016","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.det.2024.12.008_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijwd.2017.10.007","article-title":"Quality of life and sexual health in patients with hidradenitis suppurativa","volume":"4","author":"Alavi","year":"2018","journal-title":"Int J Womens Dermatol"},{"issue":"5 Suppl 1","key":"10.1016\/j.det.2024.12.008_bib3","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jaad.2015.07.047","article-title":"New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes","volume":"73","author":"van der Zee","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.12.008_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200683","article-title":"Hidradenitis suppurativa (HS) prevalence, demographics and management pathways in Australia: a population-based cross-sectional study","volume":"13","author":"Calao","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.det.2024.12.008_bib5","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4049\/jimmunol.0903907","article-title":"Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa","volume":"186","author":"Wolk","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"10.1016\/j.det.2024.12.008_bib6","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaci.2022.02.003","article-title":"Insights into hidradenitis suppurativa","volume":"149","author":"van Straalen","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.det.2024.12.008_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Prim"},{"issue":"5","key":"10.1016\/j.det.2024.12.008_bib8","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","article-title":"Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian hidradenitis suppurativa foundations","volume":"86","author":"Garg","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2024.12.008_bib9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jdin.2024.03.002","article-title":"Biomarkers of systemic inflammation are associated with disease severity and metabolic syndrome in patients with hidradenitis suppurativa","volume":"15","author":"Holgersen","year":"2024","journal-title":"JAAD Int"},{"issue":"5","key":"10.1016\/j.det.2024.12.008_bib10","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jaad.2020.07.108","article-title":"Low prescription of tumor necrosis alpha inhibitors in hidradenitis suppurativa: a cross-sectional analysis","volume":"84","author":"Orenstein","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.008_bib11","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","article-title":"Evaluating patients' unmet needs in hidradenitis suppurativa: results from the global survey of impact and healthcare needs (VOICE) project","volume":"82","author":"Garg","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.008_bib12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjd.18983","article-title":"Evidence for a \u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study","volume":"184","author":"Marzano","year":"2021","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.det.2024.12.008_bib13","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s13555-024-01209-w","article-title":"Insights into the window of opportunity and outcome measures in patients with moderate to severe hidradenitis suppurativa treated with secukinumab: a real-world study","volume":"14","author":"Haselgruber","year":"2024","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.det.2024.12.008_bib14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamadermatol.2021.4805","article-title":"Drug survival of biologics in patients with hidradenitis suppurativa","volume":"158","author":"Ring","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.008_bib15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.det.2024.12.008_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","article-title":"Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study","volume":"80","author":"Zouboulis","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.008_bib17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/bjd.17919","article-title":"Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials","volume":"181","author":"Jemec","year":"2019","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.008_bib18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1346-8138.15605","article-title":"Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: open-label phase 3 results","volume":"48","author":"Morita","year":"2021","journal-title":"J\u00a0Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.008_bib19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40257-017-0341-6","article-title":"Safety of adalimumab dosed every week and every other week: focus on patients with hidradenitis suppurativa or psoriasis","volume":"19","author":"Ryan","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.008_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000503606","article-title":"Adalimumab dose intensification in recalcitrant hidradenitis suppurativa\/acne inversa","volume":"236","author":"Zouboulis","year":"2020","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.det.2024.12.008_bib21","first-page":"615","article-title":"Increased doses of adalimumab are associated with clinical improvement of hidradenitis suppurativa","volume":"22","author":"Williams","year":"2023","journal-title":"J\u00a0Drugs Dermatol"},{"issue":"11","key":"10.1016\/j.det.2024.12.008_bib22","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15803","article-title":"Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: what's beyond cost-effectiveness?","volume":"35","author":"Roccuzzo","year":"2022","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.det.2024.12.008_bib23","article-title":"Switching from adalimumab originator to biosimilar: clinical experience in patients with hidradenitis suppurativa","volume":"11","author":"Montero-Vilchez","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"10","key":"10.1016\/j.det.2024.12.008_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/life12101518","article-title":"Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response-data from the German HS Registry HSBest","volume":"12","author":"Kirsten","year":"2022","journal-title":"Life"},{"issue":"10","key":"10.1016\/j.det.2024.12.008_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102522","article-title":"Adalimumab originator vs. biosimilar in hidradenitis suppurativa: a multicentric retrospective study","volume":"10","author":"Burlando","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.det.2024.12.008_bib26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/09546634.2011.571657","article-title":"Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa","volume":"23","author":"van Rappard","year":"2012","journal-title":"J\u00a0Dermatol Treat"},{"issue":"2","key":"10.1016\/j.det.2024.12.008_bib27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.008_bib28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/09546634.2012.683767","article-title":"Long-term efficacy of infliximab in hidradenitis suppurativa","volume":"23","author":"Paradela","year":"2012","journal-title":"J\u00a0Dermatol Treat"},{"issue":"9","key":"10.1016\/j.det.2024.12.008_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15691","article-title":"Infliximab in hidradenitis suppurativa: a systematic review and meta-analysis","volume":"35","author":"Shih","year":"2022","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.det.2024.12.008_bib30","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jaad.2019.09.071","article-title":"High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa","volume":"82","author":"Ghias","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.008_bib31","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jaad.2019.05.022","article-title":"Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa","volume":"81","author":"Oskardmay","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.008_bib32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jaad.2019.12.071","article-title":"Evaluation of adalimumab biosimilar in treatment of psoriatic arthritis with concomitant moderate to severe chronic plaque psoriasis: an open-labeled, prospective, pilot case series","volume":"83","author":"Khandpur","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.008_bib33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jamadermatol.2021.0220","article-title":"Comparing the effectiveness and safety associated with infliximab vs infliximab-abda therapy for patients with hidradenitis suppurativa","volume":"157","author":"Westerkam","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.008_bib34","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40257-020-00579-z","article-title":"Is There a role for therapeutic drug monitoring in patients with hidradenitis suppurativa on tumor necrosis factor-\u03b1 inhibitors?","volume":"22","author":"Abdalla","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.008_bib35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jaad.2019.09.012","article-title":"Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: a retrospective chart review","volume":"82","author":"Wang","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.det.2024.12.008_bib36","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1016\/j.jid.2021.04.026","article-title":"Golimumab for the treatment of hidradenitis suppurativa in patients with previous TNF-alpha treatment failure","volume":"141","author":"Melendez-Gonzalez","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.008_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15266","article-title":"Golimumab, as an alternative treatment in patients with coexisting hidradenitis suppurativa and arthritis after adalimumab failure: report of two cases","volume":"35","author":"Ramos","year":"2022","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.det.2024.12.008_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14494","article-title":"Certolizumab pegol for hidradenitis suppurativa: case report and literature review","volume":"33","author":"Holm","year":"2020","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.det.2024.12.008_bib39","first-page":"9566","article-title":"Certolizumab to treat hidradenitis suppurativa","volume":"15","author":"Shadid","year":"2023","journal-title":"Dermatol Rep"},{"issue":"1","key":"10.1016\/j.det.2024.12.008_bib40","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000511284","article-title":"Rapid response to certolizumab pegol in hidradenitis suppurativa: a case report","volume":"7","author":"Esme","year":"2021","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.det.2024.12.008_bib41","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.12688\/f1000research.21216.1","article-title":"Case report: treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches","volume":"8","author":"Tampouratzi","year":"2019","journal-title":"F1000Res"},{"issue":"10","key":"10.1016\/j.det.2024.12.008_bib42","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/14740338.2021.1924147","article-title":"A\u00a0safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs","volume":"20","author":"Holcomb","year":"2021","journal-title":"Expet Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.det.2024.12.008_bib43","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents","volume":"76","author":"Matusiak","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.008_bib44","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"issue":"10","key":"10.1016\/j.det.2024.12.008_bib45","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/exd.14619","article-title":"IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: combined results from a pre-clinical and phase II proof-of-concept study","volume":"31","author":"Kimball","year":"2022","journal-title":"Exp Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.008_bib46","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jid.2018.10.020","article-title":"Apocrine gland-rich skin has a non-inflammatory IL-17-related immune milieu, that turns to inflammatory IL-17-mediated disease in hidradenitis suppurativa","volume":"139","author":"Jenei","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"issue":"11","key":"10.1016\/j.det.2024.12.008_bib47","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.jid.2017.05.033","article-title":"Hidradenitis suppurativa is characterized by dysregulation of the Th17:treg cell Axis, which is corrected by anti-TNF therapy","volume":"137","author":"Moran","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.008_bib48","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jaad.2021.07.035","article-title":"The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris","volume":"86","author":"Navrazhina","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.008_bib49","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/bjd.18556","article-title":"Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa","volume":"182","author":"Navrazhina","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.008_bib50","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","article-title":"Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa","volume":"147","author":"Navrazhina","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"10378","key":"10.1016\/j.det.2024.12.008_bib51","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"issue":"10443","key":"10.1016\/j.det.2024.12.008_bib52","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.det.2024.12.008_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13403","article-title":"Brodalumab: a new way to inhibit IL-17 in psoriasis","volume":"33","author":"Facheris","year":"2020","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.det.2024.12.008_bib54","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.19478","article-title":"Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study","volume":"184","author":"Frew","year":"2021","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.008_bib55","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","article-title":"The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study","volume":"83","author":"Frew","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.008_bib56","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/1346-8138.15807","article-title":"Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: a possible involvement of Th17 across the spectrum of both diseases","volume":"48","author":"Yoshida","year":"2021","journal-title":"J\u00a0Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.008_bib57","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/ijd.14792","article-title":"Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure","volume":"59","author":"Arenbergerova","year":"2020","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.008_bib58","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/12034754211035667","article-title":"Treatment outcomes of IL-17 inhibitors in hidradenitis suppurativa: a systematic review","volume":"26","author":"Kashetsky","year":"2022","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.det.2024.12.008_bib59","unstructured":"MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody\u00ae sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa (press release). 2023."},{"key":"10.1016\/j.det.2024.12.008_bib60","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.563","article-title":"Long-term safety of secukinumab over five years in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis: update on integrated pooled clinical trial and post-marketing surveillance data","volume":"102","author":"Gottlieb","year":"2022","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"10.1016\/j.det.2024.12.008_bib61","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s13555-024-01207-y","article-title":"Ustekinumab in hidradenitis suppurativa: a systematic review and meta-analysis","volume":"14","author":"Masson","year":"2024","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.det.2024.12.008_bib62","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjd.21066","article-title":"High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa","volume":"187","author":"Jiang","year":"2022","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.008_bib63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000501075","article-title":"Ustekinumab with intravenous infusion: results in hidradenitis suppurativa","volume":"236","author":"Romani","year":"2020","journal-title":"Dermatology"},{"issue":"10","key":"10.1016\/j.det.2024.12.008_bib64","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1111\/jdv.19252","article-title":"Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: a phase 2 randomized study","volume":"37","author":"Kimball","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.det.2024.12.008_bib65","doi-asserted-by":"crossref","first-page":"T755","DOI":"10.1016\/j.ad.2023.06.013","article-title":"The effectiveness of guselkumab in patients with hidradenitis suppurativa under clinical practice conditions: a Spanish multicentre retrospective study","volume":"114","author":"Rivera-Diaz","year":"2023","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"10.1016\/j.det.2024.12.008_bib66","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/bjd\/ljad010","article-title":"Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study","volume":"188","author":"Dudink","year":"2023","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.008_bib67","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s13555-023-00913-3","article-title":"Efficacy and safety of risankizumab for the treatment of hidradenitis suppurativa: a phase 2, randomized, placebo-controlled trial","volume":"13","author":"Kimball","year":"2023","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.det.2024.12.008_bib68","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.det.2024.12.008_bib69","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamadermatol.2017.2392","article-title":"Canakinumab for severe hidradenitis suppurativa: preliminary experience in 2 cases","volume":"153","author":"Houriet","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.008_bib70","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1684\/ejd.2013.2018","article-title":"Pyoderma gangrenosum and concomitant hidradenitis suppurativa--rapid response to canakinumab (anti-IL-1beta)","volume":"23","author":"Jaeger","year":"2013","journal-title":"Eur J Dermatol"},{"issue":"9","key":"10.1016\/j.det.2024.12.008_bib71","first-page":"36","article-title":"Non-response to interleukin-1 antagonist canakinumab in two patients with refractory pyoderma gangrenosum and hidradenitis suppurativa","volume":"10","author":"Sun","year":"2017","journal-title":"J\u00a0Clin Aesthet Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.008_bib72","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1001\/jamadermatol.2023.5891","article-title":"Clinical data on laboratory testing for patients taking systemic immunomodulatory agents: do we order them enough or too much?","volume":"160","author":"Enos","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.det.2024.12.008_bib73","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.det.2024.12.008_bib74","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.008_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2023.07.172","article-title":"43799 efficacy and safety of upadacitinib in moderate-to-severe hidradenitis suppurativa: a phase 2, randomized, placebo-controlled study","volume":"89","author":"Kimball","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.008_bib76","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","article-title":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study","volume":"90","author":"Kirby","year":"2024","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.008_bib77","doi-asserted-by":"crossref","DOI":"10.1093\/omcr\/omad003","article-title":"Successful treatment of Hidradenitis Suppurativa with tofacitinib: two cases and a review of the literature","volume":"2023","author":"Sadeghzadeh Bazargan","year":"2023","journal-title":"Oxf Med Case Reports"},{"issue":"5","key":"10.1016\/j.det.2024.12.008_bib78","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s10875-023-01454-2","article-title":"STAT1 gain-of-function and hidradenitis suppurativa successfully managed with baricitinib","volume":"43","author":"Olbrich","year":"2023","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.det.2024.12.008_bib79","unstructured":"Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura\u00ae) in Patients with Mild-to-Moderate Hidradenitis Suppurativa (press release). March 10, 2024."},{"issue":"3","key":"10.1016\/j.det.2024.12.008_bib80","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A\u00a0review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.det.2024.12.008_bib81","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2016.06.001","article-title":"Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa","volume":"75","author":"Wong","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.008_bib82","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jac\/dkv361","article-title":"Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients","volume":"71","author":"Join-Lambert","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.det.2024.12.008_bib83","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/ijd.14036","article-title":"Ertapenem - a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa","volume":"57","author":"Braunberger","year":"2018","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.det.2024.12.008_bib84","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/jamadermatol.2023.6201","article-title":"Efficacy and durability of intravenous ertapenem therapy for recalcitrant hidradenitis suppurativa","volume":"160","author":"Nosrati","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.det.2024.12.008_bib85","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamadermatol.2020.0777","article-title":"Evaluation of hidradenitis suppurativa disease course during pregnancy and postpartum","volume":"156","author":"Lyons","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.det.2024.12.008_bib86","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1159\/000531727","article-title":"Patient perspectives on hidradenitis suppurativa and infertility: a survey study","volume":"239","author":"Masson","year":"2023","journal-title":"Dermatology"},{"issue":"2","key":"10.1016\/j.det.2024.12.008_bib87","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1001\/jamadermatol.2020.5162","article-title":"Pregnancy in hidradenitis suppurativa-patient perspectives and practice gaps","volume":"157","author":"Adelekun","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2024.12.008_bib88","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/985646","article-title":"IgG placental transfer in healthy and pathological pregnancies","volume":"2012","author":"Palmeira","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"5","key":"10.1016\/j.det.2024.12.008_bib89","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1111\/ijd.15742","article-title":"Certolizumab pegol and its role in pregnancy-age hidradenitis suppurativa","volume":"61","author":"Repetto","year":"2022","journal-title":"Int J Dermatol"},{"issue":"2","key":"10.1016\/j.det.2024.12.008_bib90","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.det.2024.12.008_bib91","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/12034754231222415","article-title":"A\u00a0practical guide to using biologics in pediatric dermatology","volume":"28","author":"George","year":"2024","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"6","key":"10.1016\/j.det.2024.12.008_bib92","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40272-023-00595-6","article-title":"Hidradenitis suppurativa in children and adolescents: an update on pharmacologic treatment options","volume":"25","author":"Chiang","year":"2023","journal-title":"Paediatr Drugs"},{"issue":"3","key":"10.1016\/j.det.2024.12.008_bib93","article-title":"Effectiveness of surgical deroofing and carbon dioxide laser in moderate-to-severe hidradenitis suppurativa patients","volume":"16","author":"Clark","year":"2024","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/j.det.2024.12.008_bib94","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","article-title":"Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial","volume":"156","author":"Bechara","year":"2021","journal-title":"JAMA Surg"},{"issue":"12","key":"10.1016\/j.det.2024.12.008_bib95","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/acr.23209","article-title":"Perioperative timing of infliximab and the risk of serious infection after elective hip and knee arthroplasty","volume":"69","author":"George","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.det.2024.12.008_bib96","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/rheumatology\/kez475","article-title":"A\u00a0meta-analysis of biologic therapies on risk of new or recurrent cancer in patients with rheumatoid arthritis and a prior malignancy","volume":"59","author":"Xie","year":"2020","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.det.2024.12.008_bib97","article-title":"Treatment of psoriasis with biologics and apremilast in patients with a history of malignancy: a retrospective chart review","volume":"18","author":"Kahn","year":"2019","journal-title":"J\u00a0Drugs Dermatol JDD"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524001086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863524001086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T17:31:01Z","timestamp":1751391061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863524001086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0733863524001086"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2024.12.008","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing Hidradenitis Suppurativa with Biologics and Small Molecule Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2024.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}